Your session is about to expire
← Back to Search
CBD for Anxiety in Breast Cancer
Study Summary
This trial is studying how well a single dose of cannabidiol (CBD) helps manage anticipatory anxiety in participants with advanced breast cancer who are about to have computed tomography (CT) or positron emission tomography (PET) scans to assess tumor burden.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2022 Phase 2 & 3 trial • 90 Patients • NCT04387617Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- My organs and bone marrow are working well.I can care for myself but may not be able to do active work.You feel a little bit anxious before getting a scan for cancer.I do not have any uncontrolled illnesses like severe infections, heart failure, or irregular heartbeats.I have liver cancer or hard-to-control diabetes.I won't drive for 12 hours after taking the study medication.I am 18 years old or older.Your total bilirubin levels are more than two times the normal limit.I am allergic to cannabidiol or ingredients in the placebo like sesame, corn, and gluten.I am scheduled for a CT or PET scan to check my cancer within 2 days of starting the study drug.I am not pregnant and will use birth control during the study.I have not used cannabis or related products within 24 hours before taking the study drug.I am currently using clobazam or valproic acid.The levels of certain liver enzymes in your blood should not be more than three times the normal limit set by the hospital.Your anxiety level, as measured by GAD-7, is 5 or higher before starting the study.I am currently taking medication for HIV.My breast cancer has spread to other parts of my body.I haven't taken any benzodiazepines within 8 hours before the study drug.I agree to use contraception while on this trial.
- Group 1: Cannabidiol
- Group 2: Placebo
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Are there vacancies available in this clinical undertaking?
"Accurate. According to information found on clinicaltrials.gov, this medical examination is still seeking participants since it was initially posted in January 19th 2022 and last modified on February 2nd of the same year. The desired number of patients for this study are 50 from a single site location."
Has the FDA sanctioned Cannabidiol for medicinal use?
"Due to the Phase 2 status of this trial, there is only some evidence indicating the safety profile of Cannabidiol. Thus, it received a score of two on our team's metric from 1-3."
Are there any other experiments that have explored Cannabidiol's efficacy?
"Presently, 79 clinical trials for Cannabidiol are underway with 16 of those studies having progressed to Phase 3. The bulk of these experiments are centred in Ribeirao Preto, Sao Paulo; however, research is being conducted across 290 locations worldwide."
How many individuals are currently undergoing treatment within this experiment?
"Yes, clinicaltrials.gov data indicate that this trial is currently enrolling patients. This research initiative was first posted on January 19th 2022 and has been most recently updated on February 2nd of the same year. 50 participants are being admitted from a solitary medical facility."
Share this study with friends
Copy Link
Messenger